Actinium Pharmaceuticals (ATNM) Gets a Buy Rating from Maxim Group

By Ryan Adsit

Maxim Group analyst Jason McCarthy maintained a Buy rating on Actinium Pharmaceuticals (ATNMResearch Report) yesterday and set a price target of $1.50. The company’s shares closed last Monday at $0.34.

According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -22.5% and a 25.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Inc., Hancock Jaffe Laboratories Inc, and Aridis Pharmaceuticals Inc.

Actinium Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $1.50.

See today’s analyst top recommended stocks >>

Based on Actinium Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $5.03 million. In comparison, last year the company had a GAAP net loss of $6.15 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells.